Table 5.
Characteristics of patients receiving Gefitinib.
| Somatic Mutational Spectrum | EGFR | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Age | Previous Chemo-therapy | Response | TTP (months) |
Survival (months) |
RAS 12/13 |
EGFR Exons 18–21 | BRAF exon 15 | MET 5′–3′ exon 14 intro-exon boundaries | Her2 Exon20 |
FISH | IHC |
| 1 | 38 | Y | PD | 1.25 | 8.85 | WT | WT | WT | WT | Y781C | ND | 0 |
| 2 | 50 | Y | PR | 2.20 | 5.70 | WT | WT | WT | WT | WT | ND | ND |
| 3 | 75 | Y | SD | 5.31 | 6.46 | WT | WT | WT | WT | WT | WT | 0 |
| 4 | 59 | Y | NE | 2.66 | 2.66 | WT | WT | WT | WT | Q795R | WT | 3 |
| W825X | ||||||||||||
| 5 | 63 | Y | SD | 12.13 | 12.13 | WT | delL747-P753insS | WT | WT | WT | Amp | ND |
| 6 | 66 | Y | PD | 2.07 | 2.43 | WT | WT | WT | WT | WT | WT | 3 |
| 7 | 63 | Y | SD | 7.74 | 9.54 | WT | delL747-P753insS | WT | WT | WT | WT | 0 |
| 8 | 72 | Y | SD | 8.46 | 11.70 | WT | R836R | WT | WT | WT | Amp | 3 |
| V843I | ||||||||||||
| 9 | 62 | Y | SD | 7.84 | 8.03 | WT | WT | WT | WT | WT | ND | 3 |
| 10 | 72 | Y | PR | 3.11 | 3.11 | WT | WT | WT | WT | WT | WT | 3 |
| 11 | 75 | Y | PD | 5.15 | 5.15 | WT | WT | WT | WT | WT | Amp | 2 |
| 12 | 66 | N | PR | 4.10 | 11.64 | WT | WT | WT | WT | WT | Gain | 2 |
| 13 | 74 | N | PD | 3.57 | 9.15 | WT | WT | WT | WT | WT | WT | 3 |
| 14 | 61 | N | PD | 1.64 | 3.74 | WT | WT | WT | WT | WT | WT | 3 |
| 15 | 70 | N | CR | 15.05 | 17.57 | G12D | WT | WT | WT | WT | WT | 3 |
| 16 | 69 | Y | PD | 0.82 | 10.75 | WT | WT | WT | WT | WT | WT | 0 |
| 17 | 63 | Y | PD | 0.75 | 2.89 | WT | WT | WT | WT | WT | WT | 3 |
| 18 | 72 | Y | NE | 4.59 | 4.59 | WT | WT | WT | WT | WT | WT | 3 |
| 19 | 59 | Y | SD | 1.48 | 3.80 | WT | WT | WT | WT | WT | WT | 2 |
Abbreviations: Y: Yes; N: No; IHC: immunohistochemistry; FISH: fluorescent in situ hybridization; ND: not determined; gain: aneuploidy; CR: complete response; PR: partial response; SD: stable disease; PR: progressive disease; NE: not evaluable.